Association between AT1 receptor gene polymorphism and left ventricular hypertrophy and arterial stiffness in

Related Experiment Video

Updated: Aug 15, 2025

Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound
10:08

Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound

Published on: December 2, 2014

16.1K

Hangjun Ou1, Danan Liu2, Guangjian Zhao1

  • 1Department of Cardiology, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, Guizhou, China.

BMC Cardiovascular Disorders
|December 28, 2022
PubMed

Insights

Essential hypertension patients with the AGTR1 GA or AA genotype show a reduced risk of left ventricular hypertrophy and arterial stiffness. This genetic variation may influence the development of these common essential hypertension complications.

Area of Science:

  • Cardiovascular Genetics
  • Hypertension Research
  • Molecular Cardiology

Background:

  • Essential hypertension (EH) is frequently associated with left ventricular hypertrophy (LVH) and arterial stiffness.
  • The angiotensin II type 1 receptor (AT1) gene (AGTR1) has been implicated in the pathophysiology of EH.

Purpose of the Study:

  • To investigate the association between AGTR1 gene polymorphisms and the occurrence of LVH and arterial stiffness in patients with EH.
  • To determine if specific AGTR1 genotypes confer differential risks for these EH complications.

Main Methods:

  • A cohort of 179 EH patients was analyzed.
  • Genotyping of the AGTR1 (rs4524238) polymorphism was performed using oral exfoliated cells and gene sequencing.
  • LVH and arterial stiffness were assessed as clinical outcomes.

Main Results:

  • Patients with the AGTR1 GG genotype exhibited a higher prevalence of LVH (41.23%) and arterial stiffness (26.32%) compared to those with GA or AA genotypes (21.54% and 12.31%, respectively).
  • Multivariate logistic regression, adjusted for age, gender, and diabetes, indicated that the AGTR1 GA or AA genotype was independently associated with a significantly lower risk of LVH (OR=0.344) and arterial stiffness (OR=0.371).
  • The observed genotype frequencies were in Hardy-Weinberg equilibrium (P=0.291).

Conclusions:

  • The AGTR1 genotype is associated with the risk of developing LVH and arterial stiffness in patients with essential hypertension.
  • EH patients carrying the AGTR1 GA or AA genotype demonstrate a reduced risk for these cardiovascular complications compared to those with the GG genotype.
Abstract

Keywords:
AGTR1Arterial stiffnessCohort studyEssential hypertensionGenetic polymorphismHypertensionLeft ventricular hypertrophy

More Related Videos

Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy10:35

Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy

Published on: October 19, 2016

10.6K
A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.1K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
808
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
30
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
34
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
23
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
503